Key Points
- Insider sale: Director Derek Maetzold sold 5,115 shares on November 25 at an average price of $40.05 for a total of $204,855.75, reducing his stake by 10.04% to 45,822 shares valued at about $1.84 million.
- Recent results: Castle reported a quarterly EPS of ($0.02) on November 3, beating the ($0.34) estimate and posting revenue of $80.55 million versus $71.06 million expected.
- Market/analyst view: The stock trades near its 52-week high (~$40.51) with a $1.17 billion market cap, and analysts have a consensus "Moderate Buy" rating with an average price target of $37.43.
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 5,115 shares of the company's stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $40.05, for a total transaction of $204,855.75. Following the sale, the insider directly owned 45,822 shares of the company's stock, valued at $1,835,171.10. This represents a 10.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Castle Biosciences Trading Up 0.0%
NASDAQ:CSTL opened at $39.94 on Thursday. The stock has a market cap of $1.17 billion, a PE ratio of -88.76 and a beta of 1.12. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.47 and a quick ratio of 6.31. The stock's 50-day moving average is $27.40 and its two-hundred day moving average is $21.95. Castle Biosciences, Inc. has a fifty-two week low of $14.59 and a fifty-two week high of $40.51.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.32. The business had revenue of $80.55 million during the quarter, compared to analysts' expectations of $71.06 million. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%. Castle Biosciences has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research firms recently commented on CSTL. Zacks Research upgraded Castle Biosciences from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 20th. BTIG Research lifted their target price on Castle Biosciences from $32.00 to $38.00 and gave the company a "buy" rating in a research note on Tuesday, November 4th. Canaccord Genuity Group restated a "buy" rating and issued a $37.00 price objective on shares of Castle Biosciences in a report on Tuesday, September 9th. Robert W. Baird raised their target price on Castle Biosciences from $39.00 to $41.00 and gave the stock an "outperform" rating in a report on Tuesday, November 4th. Finally, Wall Street Zen upgraded shares of Castle Biosciences from a "sell" rating to a "hold" rating in a research report on Sunday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $37.43.
View Our Latest Research Report on Castle Biosciences
Hedge Funds Weigh In On Castle Biosciences
A number of large investors have recently modified their holdings of the business. CWM LLC raised its holdings in Castle Biosciences by 835.0% during the first quarter. CWM LLC now owns 4,142 shares of the company's stock worth $83,000 after acquiring an additional 3,699 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Castle Biosciences during the 1st quarter worth about $235,000. Mackenzie Financial Corp increased its stake in shares of Castle Biosciences by 30.6% during the first quarter. Mackenzie Financial Corp now owns 27,460 shares of the company's stock worth $550,000 after purchasing an additional 6,440 shares during the period. XTX Topco Ltd bought a new stake in shares of Castle Biosciences in the first quarter valued at about $393,000. Finally, Harbour Investments Inc. bought a new position in Castle Biosciences during the first quarter worth about $50,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.
About Castle Biosciences
(
Get Free Report)
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
